期刊
BRITISH JOURNAL OF PHARMACOLOGY
卷 169, 期 4, 页码 719-735出版社
WILEY
DOI: 10.1111/bph.12155
关键词
non-invasive imaging; cancer pharmacology; bioluminescence; ultrasound; PET; MRI
资金
- Cancer Research UK
- Engineering and Physical Sciences Research Council
- Yorkshire Cancer Research
- EPSRC [EP/I000623/1] Funding Source: UKRI
- Engineering and Physical Sciences Research Council [EP/I000623/1] Funding Source: researchfish
Molecular and non-invasive imaging are rapidly emerging fields in preclinical cancer drug discovery. This is driven by the need to develop more efficacious and safer treatments, the advent of molecular-targeted therapeutics, and the requirements to reduce and refine current preclinical in vivo models. Such bioimaging strategies include MRI, PET, single positron emission computed tomography, ultrasound, and optical approaches such as bioluminescence and fluorescence imaging. These molecular imaging modalities have several advantages over traditional screening methods, not least the ability to quantitatively monitor pharmacodynamic changes at the cellular and molecular level in living animals non-invasively in real time. This review aims to provide an overview of non-invasive molecular imaging techniques, highlighting the strengths, limitations and versatility of these approaches in preclinical cancer drug discovery and development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据